Conmed (CNMD) Liabilities and Shareholders Equity (2010 - 2026)

Conmed (CNMD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 0.75% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $9.3 billion (up 0.94% YoY), and the FY2025 full-year result was $2.3 billion, up 0.85% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $2.3 billion, roughly flat from $2.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 billion in Q2 2025 and bottomed at $1.8 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $2.3 billion (2024), against an average of $2.3 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 30.67%; it then slipped 1.6% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.3 billion in 2022, then gained by 0.11% to $2.3 billion in 2023, then gained by 0.27% to $2.3 billion in 2024, then gained by 0.85% to $2.3 billion in 2025, then declined by 0.46% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.

Peer Comparison